Guidetti Matteo, Hilfiker Rolf, Kuentz Martin, Bauer-Brandl Annette, Blatter Fritz
Solvias AG, Solid-State Development Department, Römerpark 2, Kaiseraugst CH- 4303, Switzerland; Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, Odense 5230, Denmark.
Solvias AG, Solid-State Development Department, Römerpark 2, Kaiseraugst CH- 4303, Switzerland.
Eur J Pharm Sci. 2024 Apr 1;195:106722. doi: 10.1016/j.ejps.2024.106722. Epub 2024 Feb 7.
Posaconazole is a broad-spectrum antifungal agent exhibiting rich polymorphism. Up to now, a total of fourteen different crystal forms have been reported, sometimes with an ambiguous nomenclature, but less is known about their properties and stability relationships. Investigating the solid-state of a drug compound is essential to identify the most stable form under working conditions and to prevent the risk of undesired solid-phase transformations under processing and storage. In this paper, we study posaconazole polymorphism by providing a description of its polymorphs, hydrates, and solvates. Powder X-ray diffraction (PXRD), dynamic vapor sorption (DVS), spectroscopic and thermal techniques were employed to characterize the different forms. In addition, the solid-phase transformations of posaconazole in aqueous suspensions were studied by means of Raman microscopy. Surprisingly, we found that Form S, the crystal form contained in the marketed oral suspension, is not the most stable form in water. Form S readily converts to a more stable hydrate, i.e. Form A, after storage in water for two weeks. In the commercial oral formulation the conversion between the two forms is prevented by the presence of polysorbate 80. Such insights into the stabilizing excipient effects beyond particle dispersion are critical to formulators.
泊沙康唑是一种具有丰富多晶型现象的广谱抗真菌剂。截至目前,总共已报道了十四种不同的晶型,其命名有时并不明确,而且人们对它们的性质和稳定性关系了解较少。研究药物化合物的固态对于确定工作条件下最稳定的晶型以及防止在加工和储存过程中发生不期望的固相转变风险至关重要。在本文中,我们通过描述泊沙康唑的多晶型物、水合物和溶剂化物来研究其多晶型现象。采用粉末X射线衍射(PXRD)、动态蒸汽吸附(DVS)、光谱和热分析技术对不同晶型进行表征。此外,通过拉曼显微镜研究了泊沙康唑在水悬浮液中的固相转变。令人惊讶的是,我们发现市售口服混悬液中所含的晶型S在水中并非最稳定的晶型。晶型S在水中储存两周后很容易转化为更稳定的水合物,即晶型A。在商业口服制剂中,聚山梨酯80的存在阻止了两种晶型之间的转化。这种对超出颗粒分散作用的稳定化辅料效应深入了解对配方设计师来说至关重要。